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PRÁTICA CLINICA
general recommendations concerned the assessment of
infectious risk before and while on biologics, the pro-
cedures in case of suspected infection and the mana -
gement of biologics during infectious complications.
Six specific recommendations were developed for res-
piratory, urinary, gastrointestinal, skin, osteoarticular
and disseminated infections.
Conclusion: These fifteen recommendations are in-
tended to help rheumatologists in the management of
infections in patients on biological therapy. They inte-
grate an extensive literature review, expert opinion and
inputs from Portuguese rheumatologists.
Keywords: Biologics; Infections; Treatment; Recom-
mendations.
IntroductIon
Patients with systemic inflammatory rheumatic disease
(SIRD) have increased morbidity and mortality due to
infections. Highly active and long standing diseases are
associated with amplified risk of infection. Death from
infections in patients with Rheumatoid Arthritis (RA)
is twice more common than in general population. In
other SIRDs such as Systemic Lupus Erythematosus
(SLE), Psoriatic Arthritis (PsA), Ankylosing Spondyli-
tis (AS) and systemic Vasculitis, infections have also
been found to be a major cause of death. Additionally,
SIRD patients have significantly increased risk of being
hospitalized due to a serious infection. This increased
risk can be attributed partly to the aberrant immune
system and to the effect of immunosuppressive drugs
used in the treatment of these diseases1–5.
Treatment with biological agents is associated with
a small, but statistically significant increase of serious
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AbstrAct
Introduction: Infections are a major cause of morbi dity
and mortality in systemic inflammatory rheumatic di -
seases and the management of infectious complications
in patients under biological therapies deserves parti -
cular attention.
Objective:Develop evidence-based recommendations
for the management of infections in rheumatic patients
receiving biological therapies.
Methods: A search in PubMed (until 10 November
2014) and EMBASE (until 20 December 2014) databas-
es was performed. Patients with systemic inflammato-
ry rheumatic diseases treated with approved biologics
in whom infections occurred were included. Search re-
sults were submitted to title and abstract selection, fol-
lowed by detailed review of suitable studies. Informa-
tion regarding presentation of the infectious complica-
tion, its diagnosis, treatment, and outcome, as well as
maintenance or discontinuation of the biological agent
was extracted and subsequently pooled according to
the type of infection considered. Results of literature
review were presented and critically reviewed in a dedi -
cated meeting by a multidisciplinary panel. Recom-
mendations were then formulated using the Delphi
method. Finally, the level of agreement among rheuma-
tologists was voted using an online survey.
Results: Fifteen recommendations were issued. Nine
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infectious6. The risk is particularly high for some
oppor tunistic infections and during the first months
on biologics7–9.
objectIve
Develop evidence-based recommendations for the
management of infections in SIRD patients receiving
biological therapies.
methods
A systematic literature review (SLR) was performed,
focused on the management of infections in rheuma -
tic patients while on biological therapies. We searched
in PubMed (until 10 November 2014) and EMBASE
(until 20 December 2014) databases. We included
adult patients with SIRD (RA, PsA Spondyloarthritis,
Juvenile Idiopathic Arthritis and SLE), treated with
appro ved biologics. The biological agents considered
were TNF inhibitors (TNF-i), Rituximab, Abatacept,
Tocilizumab, Belimumab, Anakinra and Ustekinu mab.
The outcomes of interest were respiratory, urinary, gas-
trointestinal, skin and soft tissue, osteoarticular, oppor -
tunistic (viral and others) and disseminated infections
as well as viral hepatitis. Regarding the occurrence of
infections we were particularly interested in their pre-
sentation, diagnostic procedures, treatment, mainte-
nance or discontinuation of biological therapy and
their outcome. We included randomized controlled
trials, cohort studies, case-control studies and case se-
ries. The exclusion criteria were: non-rheumatic di -
sease, no biological therapy, clinical cases, editorials,
review articles, opinion pieces, letters, and no refe -
rence to the outcomes of interest. Eight independent
reviewers performed a selection by title and abstract.
Data were subsequently extracted from the eligible
studies and pooled according to the type of infection.
Thereafter, a descriptive analysis was performed. 
SLR results were presented and critically reviewed
by a multidisciplinary panel with 63 participants, in-
cluding rheumatologists, an infectious diseases expert,
a pulmonologist, other health professionals and pa-
tient representatives. The taskforce was subsequently
divided in 6 breakout groups: each one discussed one
topic and proposed recommendations. Preliminary
statements were afterwards submitted to the appraisal
of the entire taskforce and voted according to the Del-
phi method. A minimum concordance rate of 75% was
considered necessary for the approval of each state-
ment as a final recommendation. When below this le -
vel of agreement, the content and phrasing of each
statement were discussed and reformulated until a
suitable concordance rate was attained. Then, each
statement was organized according to general princi-
ples and infection specific recommendations. Recom-
mendations were sent to all rheumatologists and the fi-
nal agreement was voted online in a 10-point numeri -
cal scale (one – fully disagree to ten – totally agree) by
55 rheumatologists.
results
Nine hundred and thirty one abstracts were retrieved.
After title and abstract selection 157 manuscripts en-
tered the detailed review, but 13 were excluded, leav-
ing 144 papers in this phase (Figure 1).
Of the 144 papers included, 80 concerned to res-
piratory tract infections, 37 to urinary tract infections,
21 to gastrointestinal infections, 24 to viral hepatitis,
33 to skin and soft tissue infections, 13 to osteoarticu -
lar infections, 47 to opportunistic infections (viral and
others) and 6 to disseminated infections. Table I sum-
marizes study distribution according to the type of in-
fections and biological therapy. Of note, several papers
concerned more than one type of infection and more
than one type of biological agent.
recommendAtIons
Nine general principles and six infection specific recom-
mendations were issued, reaching a high level of agree-
ment among Portuguese Rheumatologists (Table II).
GenerAl prIncIples
1. OVERALL INFECTION RISK MUST BE ASSESSED IN
EVERY RHEUMATIC PATIENT EITHER CANDIDATE OR
ON BIOLOGICAL THERAPY. LEVEL OF EVIDENCE:
3A, GRADE OF RECOMMENDATION: C.
The particular risk of infectious complications in pa-
tients with SIRD is estimated to be about 2-fold hi gher
than in the general population.10,11 Identified risk fac-
tors include demographics and disease characteristics,
comorbidities, medication as well as the epidemiolo -
gical context (Table III). Along with older age (>65
years) and impaired function, the presence of diabetes
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fIGure 1. The search strategy for the systematic review
tAble I. dIstrIbutIon of the Included studIes AccordInG to the bIoloGIcAl AGent And type of
InfectIon
Type of infection Abatacept Anakinra Belimumab RTX TCZ TNF-i Total
Respiratory 13 2 4 15 14 35 80
Urinary 9 1 1 10 3 26 37
Gastrointestinal 5 0 0 7 5 9 21
Viral hepatitis 1 - 4 19 24
Skin/soft tissue 1 - 1 8 6 20 33
Osteoarticular 2 - - 2 2 9 13
Opportunistic (viral) 2 - - 5 2 7 14
Opportunistic (others) 3 - 1 3 1 26 33
Disseminated 1 - - - 1 5 6
RTX – Rituximab, TCZ – Tocilizumab, TNF-i – Tumour Necrosis Factor inhibitors. Some studies are quoted in more than one column
because they address more than one class of biological drug or more than one type of infection.
mellitus, chronic pulmonary disease, impaired renal
function, previous infections, alcoholism and hy-
pogammaglobinaemia, are independently associated
with the susceptibility to infections.  Local specific in-
fection risk factors such as bronchiectasis, urethral
catheterization, vesicoureteral reflux and other anato -
mical changes, history of skin ulcers, previous septic
arthritis and prosthetic joint must also be addressed in
infection risk evaluation 11,12. In addition, exposure to
medication should also be part of overall risk assess-
ment.13 Glucocorticoids (GCs) and some conventional
synthetic disease-modifying antirheumatic drugs 
(csDMARDs) may impair the response to pathogens
and consequently predispose to infection. Use of me -
dium to high dose GCs, particularly in prolonged use,
has been linked to serious infections requiring hospi-
talization.14 In a large cohort study, a dose-dependent
effect was suggested. The incidence rate ratio (IRR) of
serious infections was significantly increased in patients
treated with GCs, being higher in patients treated with
≥15 mg/day (IRR=4.7) compared to patients treated
with 7.5-14 mg/day (IRR=2.1)15,16. For low-dose GCs
(in some studies defined as ≤5 mg and others as ≤7.5
mg), there was no increased risk, or the risk was only
slightly increased.6 There is no conclusive data sup-
porting the notion that methotrexate use (and other 
csDMARDs) increases the overall risk of infection17,18. 
For assessing the risk of infection in this population,
it is also very important to evaluate the previous vacci-
nation status13.
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tAble II. recommendAtIons for the mAnAGement of InfectIons In rheumAtIc pAtIents receIvInG
bIoloGIcAl therApIes
Level of Agreement 
Recommendations evidence Grade mean (SD)
General
1. Overall infection risk must be assessed in every rheumatic patient either 3a C 9.79 (0.62)
candidate or on biological therapy.
2. Screening of chronic infections – tuberculosis, HIV, HBV, and HCV – should be 4 C 9.84 (0.42)
performed in accordance to the national guidelines prior to the introduction of 
biological therapy. Screening of other infections can be considered in view of the 
epidemiological context.
3. In the event of suspected active infection, the severity of the situation must be 5 D 9.59 (0.63)
evaluated and postponing the administration of the biologic is advised.
4. There should be a high index of suspicion for opportunistic infections. 5 D 9.45 (0.95)
5. Identification of the causative agent is recommended whenever possible. 5 D 9.45 (0.72)
6. Biological therapy should be discontinued at least during antimicrobial therapy. 5 D 8.82 (1.49)
7. Reintroduction of biological therapies after resolution of an infectious episode 5 D 9.38 (1)
should be decided on a case-by-case basis, taking into account the activity of the 
rheumatic disease and the risk of reinfection.
8. Permanent discontinuation of biological therapy should be considered in severe 5 D 9.44 (0.76)
or recurrent infections.
9. The diagnostic / therapeutic decision-making should be shared with the patient. 5 D 9.48 (0.83)
Specific
1. Upper or lower respiratory infections. If no signs of severity consider 5 D 9.35 (0.99)
symptomatic treatment and/or empirical oral antibiotic therapy and monitor 
evolution. In severe infections intravenous antibiotic therapy should be promptly 
initiated and whenever possible guided by antibiotic susceptibility testing. 
2. Urinary tract infections. If severe, intravenous antibiotics are recommended. 5 D 9.45 (0,78)
Consider repeat urine culture prior to reintroduction of the biologic. Evidence is 
lacking regarding management of asymptomatic bacteriuria in rheumatic patients 
under biologics.
3. Gastrointestinal infections. If severe antibiotics directed to the identified causal 5 D 9.04 (1.17)
agent or empirical broad-spectrum antibiotics should be started. In the event of 
elevated transaminases of unknown aetiology viral hepatitis screening should be 
repeated. In presence of active viral hepatitis biological therapy should be 
discontinued until full evaluation.
4. Skin and soft tissue. Oral or intravenous empirical antibiotics should be initiated 4 C 9.32 (1.15)
according to severity, with further adjustment guided by susceptibility tests.
5. Osteoarticular infections. Intravenous broad-spectrum empirical antibiotherapy 2b B 9.61 (0.68)
must be promptly started with subsequent adjustment according to antibiotic 
susceptibility testing. Opportunistic infections and associated osteomyelitis have 
to be considered in the evaluation of joint infections. Assessment by an 
orthopaedic surgeon is recommended, particularly in patients with osteomyelitis 
or joint prosthesis.
6. Disseminated infection. Epidemiological context should guide diagnostic studies. 4 C 9.61 (0.68)
Immunosuppressive treatment must be stopped and broad-spectrum empirical 
antibiotherapy introduced immediately. In the absence of clinical response after 
48-72 hours, consider less common agents such as fungi, viruses, parasites and 
mycobacteria.
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2. SCREENING OF CHRONIC INFECTIONS –
TUBERCULOSIS, HIV, HBV, AND HCV – SHOULD
BE PERFORMED IN ACCORDANCE TO THE NATIONAL
GUIDELINES PRIOR TO THE INTRODUCTION OF
BIOLOGICAL THERAPY. SCREENING OF OTHER
INFECTIONS CAN BE CONSIDERED IN VIEW OF THE
EPIDEMIOLOGICAL CONTEXT. LEVEL OF EVIDENCE:
4, GRADE OF RECOMMENDATION: C.
The presence of active infections is a contraindication
for starting biological therapy. Suspension of the bio-
logical therapy is mandatory in all active viral infec-
tions with organ damage. Chronic infections, such as
tuberculosis, HIV, hepatitis B and C also pose cons -
traints to the use of these medications and must be
proactively screened19,20.Until 2014, Portugal was a
country with an intermediate incidence rate of tuber-
culosis and specific recommendations for screening
and treatment of latent tuberculosis were published21.
Although infection by a hepatotropic virus (HBV 
and HCV) is usually considered a contraindication 
for anti-TNF therapies, their use can be justified 
after a careful risk/benefit assessment. Recommenda-
tions for screening before TNF inhibitors seem to be
quite safe in patients with chronic hepatitis C with low
to mode rate chronic activity on histopathological exa -
mination (Knodell Histology Activity Index ≤12, with
or without fibrosis) independently of viral load22–31. In
our SLR we found 9 studies including a total of 52 pa-
tients with chronic hepatitis C treated with TNF-i, 48
of them did not receive prophylaxis or treatment for
hepatitis C. After a medium follow up of 18 months
only one patient stopped the biologic. The others did
not develop neither symptoms of viral liver disease nor
persistent ele vation of liver enzymes (more than twice
the upper limit of normal), though some variation of
liver enzymes was seen (less than twice the upper 
limit of normal). Although these studies suggest a good
safety profile for anti-TNF therapies in patients with
HCV infection, their use should be monitored careful-
ly23–31. Safety data with other biological agents are
scarce.
Concerning patients with chronic HBV infection, the
introduction of biological therapy should be done only
after a thorough clinical and laboratorial assessment,
evaluation by a liver disease specialist and, when indi-
cated, initiation of appropriate antiviral therapy/pro-
phylactic antiviral therapy32–34. Although rarely, reacti-
vation of “resolved” hepatitis B (AgHBs negative/anti-
-HBc positive) can also occur under biologics and
guidelines for the screening and management of those
patients were published35,36. Of our SLR we obtained in-
formation from 19 studies, corresponding to a total of
527 patients with chronic hepatitis B infection or past
“resolved” hepatitis B. In total, 28 out of 505 patients
(5.5%) under TNF-i reactivated hepatitis B after a mean
follow-up of 18.5 months (10 under chemoprophy-
laxis) and no recurrence was seen in patients with “re-
solved” hepatitis B 25,26,28,29,31,37–48.Of 8 patients medica -
ted with Abatacept, those without prophylaxis, had a
reactivation of hepatitis B (n=4).49 Fourteen patients
treated with Rituximab had no reactivation of hepati-
tis 50.
tAble III. IdentIfIed rIsk fActors for specIfIc InfectIons
Specific infections Risk Factors
Upper or lower respiratory Immunosuppression; COPD/Asthma; Diabetes mellitus and Heart Disease.
infections
Urinary tract infections Age ≥ 65 years; PDN ≥ 5-10mg or concomitant DMARDs; Disease duration> 10 years;
COPD/Asthma; Smoking; Diabetes mellitus; Heart disease; Chronic renal disease;
Recurrent infections; Charlson comorbidity index ≥2; Hypogamaglobulinemia or low IgG
(in case of Rituximab).
Skin and soft tissue Diabetes mellitus; Prior skin infection; GCs; Advanced age. 
infections
Osteoarticular infections Prosthesis; Opportunistic infections; GCs (PDN > 10mg); Advanced age; Existence of
extra-articular manifestations (in RA); Depletion of B cells.
Disseminated infection Advanced age; Longstanding rheumatic disease; Recurrent infections; Concomitant
DMARDs and GC.
COPD – chronic obstructive pulmonary disease; PDN – prednisolone.
3. IN THE EVENT OF SUSPECTED ACTIVE INFECTION,
THE SEVERITY OF THE SITUATION MUST BE
EVALUATED AND POSTPONING THE ADMINISTRATION
OF THE BIOLOGIC IS ADVISED. LEVEL OF EVIDENCE:
5, GRADE OF RECOMMENDATION: D.
There is some evidence that under biological therapy
infections may have an atypical presentation and a
more severe course 51,52. In the event of a suspected ac-
tive infection, a careful clinical evaluation must be done
and appropriate additional tests must be carried out in
order to clearly identify the type and location of infec-
tion. The presence of signs of severe illness such as fever
(body temperature >38.3°C) or hypothermia (body
temperature <36ºC), hypotension, tachycardia, tachy -
pnea, hypoxemia or abnormal state of consciousness,
must be evaluated 52–54. Although we could not always
clearly identify in the literature information regarding
the action taken with respect to the administration of
biological drug in a patient with suspected infection,
the panel considered advisable to postpone the admi -
nistration of the biologic until the severity of the situa -
tion is clarified as well as during antibiotic therapy.
4. THERE SHOULD BE A HIGH INDEX OF SUSPICION
FOR OPPORTUNISTIC INFECTIONS. LEVEL OF
EVIDENCE: 5, GRADE OF RECOMMENDATION: D.
Opportunistic infections should always be suspected in
immunocompromised patients. The epidemiologic
context must be taken into account since there is a geo -
graphical variability in the incidence of some oppor-
tunistic infections such as tuberculosis 55.
Concerning viral opportunistic infections the SLR
depicted 14 studies (population range from 4 to 59066
patients, mostly with RA). The rate of opportunistic in-
fections for each biological agent ranged between 0.2-
-6.25% and Herpes Zoster was the main microorga -
nism identified. In 3 studies the biological agent was
suspended and in 1 study maintained. Most studies
showed a good outcome with the exception of 3 pa-
tients under Rituximab and John Cunningham (JC)
virus infection, who had a fatal outcome.
The main risk factor identified for viral opportunis-
tic infections was concomitant therapy with GCs 
in a dosage greater than or equal to 10 mg/day and 
csDMARDs39,56–68.
Regarding non-viral opportunistic infections, we re-
trieved 40 studies with a population range from 2 to
141.134 patients, also mostly with RA. Opportunistic
infections were reported in 0.23% of the patients. The
most common bacterial agents were nontuberculous
mycobacteria followed by Mycobacterium tuberculosis,
either pulmonary or extra-pulmonary/disseminated in-
fections. The most common fungal agents were Pneu-
mocystis jirovecii and Candida spp. There were also re-
ports of infection caused by Listeria spp, Leishmania
spp, Cryptococcus spp, Salmonella spp and Histoplasma
spp. Of the 460 patients with non-viral opportunistic
infections, 38 had a fatal outcome 39,57,62,69–96.
5. IDENTIFICATION OF THE CAUSATIVE AGENT IS
RECOMMENDED WHENEVER POSSIBLE. LEVEL OF
EVIDENCE: 5, LEVEL OF RECOMMENDATION: D.
A wide variety of microorganisms can cause infections
in SIRD patients under biologics. A rapid and accurate
diagnosis of infection and identification of the causative
microorganism is crucial to ensure effective antimicro-
bial therapy. Thus, cultures, serological tests or even
more invasive diagnostic procedures should be per-
formed before starting empirical treatment, in order to
identify the causative agent and its susceptibility97. This
way, it will be possible to accurately determine the need
for specific antimicrobial therapy and treatment dura-
tion, to adjust treatment using the narrowest spectrum
and shortest duration of therapy, and switch to oral
agents as soon as possible98.
6. BIOLOGICAL THERAPY SHOULD BE DISCONTINUED
AT LEAST DURING ANTIMICROBIAL THERAPY. LEVEL
OF EVIDENCE: 5, LEVEL OF RECOMMENDATION: D.
Most studies did not specify whether biological agent
was stopped or not. Nevertheless, the panel conclud-
ed that it is reasonable to discontinue the biological
agent during the treatment of infections with antimi-
crobials, specifically in case of moderate to severe, re-
current or opportunistic infections.
7. REINTRODUCTION OF BIOLOGICAL THERAPIES
AFTER RESOLUTION OF AN INFECTIOUS EPISODE
SHOULD BE DECIDED ON A CASE-BY-CASE BASIS,
TAKING INTO ACCOUNT THE ACTIVITY OF THE
RHEUMATIC DISEASE AND THE RISK OF REINFECTION.
LEVEL OF EVIDENCE: 5, LEVEL OF
RECOMMENDATION: D.
After the occurrence of a serious bacterial infection, the
biological therapy should not be started until complete
clinical resolution. In the absence of signs of infection,
the biologic is usually started one week after stopping the
anti-infective treatment19,99. Given the scarcity of da ta, we
cannot recommend the reintroduction of bio lo gi cal the -
rapies after an episode of active tuberculosis. In this case
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reintroduction should be decided on a case-by-case ba-
sis and only after the complete normalization of all clini -
cal, radiological and laboratorial signs of acti ve disease.
A multidisciplinary approach should be sought.
8. PERMANENT DISCONTINUATION OF BIOLOGICAL
THERAPY SHOULD BE CONSIDERED IN SEVERE OR
RECURRENT INFECTIONS. LEVEL OF EVIDENCE: 5,
LEVEL OF RECOMMENDATION: D.
There is still a lack of evidence in the literature regar -
ding the permanent discontinuation of the biological
therapy due to infections. The panel consider that per-
manent discontinuation should be pondered in all pa-
tients with severe or recurrent infections. The indivi -
dual risk factors for infection such as age and comor-
bidities, the epidemiologic context, the SIRD and di -
sease activity, as well as concomitant medications (GCs
and csDMARDs) should be taken in account. 
9. THE DIAGNOSTIC/THERAPEUTIC DECISION-MAKING
SHOULD BE SHARED WITH THE PATIENT. LEVEL OF
EVIDENCE: 5, LEVEL OF RECOMMENDATION: D.
Shared decision making is an approach where clini-
cians and patients share the best available evidence
when faced with the task of making decisions. Despite
the lack of evidence regarding the best management of
infections in patients under biological therapy, patients
should be encouraged to learn about different treat-
ment options, their benefits and harms, and commu-
nicate their preferences. Therefore, shared decision-
-making can ensure that the decision taken meets the
clinical as well as psychosocial needs of the patient.
specIfIc InfectIons
1. UPPER AND LOWER RESPIRATORY INFECTIONS.
IF NO SIGNS OF SEVERITY CONSIDER SYMPTOMATIC
TREATMENT AND/OR EMPIRICAL ORAL ANTIBIOTIC
THERAPY AND MONITOR EVOLUTION. IN SEVERE
INFECTIONS INTRAVENOUS ANTIBIOTIC THERAPY
SHOULD BE PROMPTLY INITIATED AND WHENEVER
POSSIBLE GUIDED BY ANTIBIOTIC SUSCEPTIBILITY
TESTING. LEVEL OF EVIDENCE: 5, LEVEL OF
RECOMMENDATION: D.
From the data of the SLR performed, we conclude that
infections of the upper respiratory tract were the most
frequently found in patients treated with biological
agents. Of the 95.533 patients under biologics, there
were 10.292 (10.77%) cases of respiratory infections,
mostly upper respiratory infections occurring in 2896
(3.03%) cases and, more specifically, nasopharyngitis
in 2059 (2.16%) cases. Severe pneumonia was repor -
ted less frequently in 863 (0.9%) patients, and in 
all cases the biological agent was interrupted and pa-
tients admitted for intravenous (iv) antibiotic thera-
py3,8,56,57,61–68,70,72,73,76,78,79,81–84,86,90,96,100–146.
In patients with upper or lower respiratory tract in-
fections, without signs of severity, either symptomatic
treatment or oral antibiotics, depending on the type of in-
fection, are acceptable therapeutic options (Table IV). The
choice of the antibiotic should follow the existing stan-
dards of antibiotic treatment for different types of infec-
tion117,118,134,147. These patients need to be monitored tight-
ly and if there is no clinical improvement or if clinical
worsening occurs, the patient should be hospitalized and
iv broad spectrum antibiotics administered92,118,134,148. The
administration of the biologic must be postponed at least
until the infection is resolved and always during anti biotic
therapy, as mentioned before82,130,147,148.
2. URINARY TRACT INFECTIONS. IF SEVERE,
INTRAVENOUS ANTIBIOTICS ARE RECOMMENDED.
CONSIDER REPEAT URINE CULTURE PRIOR TO
REINTRODUCTION OF THE BIOLOGIC. EVIDENCE
IS LACKING REGARDING MANAGEMENT OF
ASYMPTOMATIC BACTERIURIA IN RHEUMATIC
PATIENTS UNDER BIOLOGICS. LEVEL OF EVIDENCE
5, GRADE OF RECOMMENDATION: D.
Thirty-seven studies reported urinary tract infections
(UTIs) in patients while taking biological treatment.
These studies included a total of 59680 patients with
identification of 778 UTIs, 41 (5%) of them classified
as serious, including 3 urinary sepsis, one fatal. 
Biological treatment was maintained in 5 studies 
despite the reported infection. None of the studies 
addressed the problem of asymptomatic bacte -
riuria8,57,61–66,81,83,84,90,92,103,110,112,114–116,119,121,123,125,128,129,132,136–
138,140,142,146,149–151.
The panel considered important the collection of
urine culture before initiating antibiotic therapy, while
ordering other tests should depend on the clinical
mani festations. The choice of the antibiotic should fol-
low the guidelines for the general population (Table
IV). None of the studies addressed the problem of
asymptomatic bacteriuria, therefore, there is currently
no evidence on its best approach.
3. GASTROINTESTINAL INFECTIONS. IF SEVERE,
ANTIBIOTICS DIRECTED TO THE IDENTIFIED CAUSAL
AGENT OR EMPIRICAL BROAD-SPECTRUM
ANTIBIOTICS SHOULD BE STARTED. IN THE EVENT
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tAble Iv. suGGested empIrIc AntIbIotIc therApy for communIty AcquIred InfectIons
Upper respiratory tract Acute bacterial rhinosinusitis163
FIRST LINE – Amoxicillin with or without Clavulanate, PO, for 5 to 10 days.
ALTERNATIVE (if penicillin allergy) – Doxycycline PO or a respiratory quinolone.
Lower respiratory tract Community-Acquired Pneumonia164
FIRST LINE – Amoxicillin 1g PO tid plus one of the following:
Azithromycin 500mg/day PO; Clarithromycin 500mg PO bid or Doxycycline 200mg PO
first dose and then 100mg bid.
ALTERNATIVE† – Levofloxacin 500mg PO qd or Moxifloxacin 400 mg PO qd164
DURATION: 7 days.
Community-Acquired Pneumonia requiring hospitalization¤ 165
NON-ICU PATIENTSµ – Aminopenicillin ± Macrolide or Aminopenicillin/b-lactamase inhibitor
± Macrolide or Non-antipseudomonal cephalosporin or Cefotaxime/Ceftriaxone ±
Macrolide; Levofloxacin/Moxifloxacin or Penicillin G ± macrolide.
DURATION: 8 days.
Urinary tract Acute uncomplicated cystitis166–168
FIRST LINEo – Fosfomycin trometamol 3g PO single dose; Nitrofurantoin macrocrystal
100 mg PO qid for 5-7 days; Amoxicillin/Clavulanate 500/125mg PO tid for 5-7 days;
TMP-SMX◊ 160/800 mg PO bid 3 days.
ALTERNATIVE – Ciprofloxacin 250 mg PO bid 3 days; Levofloxacin 250 mg PO qid 3 days;
Ofloxacin 200 mg PO bid 3 days; Cephalosporin (e.g. cefuroxime) 500 mg PO bid 3 days.
If failure of empirical therapy after 1-3 days or in severe conditions, use: Fluoroquinolone
(if not used initially); Cephalosporin (3rd generation) or Carbapenem ± Aminoglycoside.166
Mild and moderate uncomplicated pyelonephritis167,168
Ceftriaxone 1g im or iv single dose followed by Cefuroxime 500mg PO bid, 7-14 days;
Levofloxacin 750 mg PO qid 5 days.
DURATION: 1-2 weeks.
Severe acute pyelonephritis (complicated with sepsis)168
FIRST LINE – Ceftriaxone 2g iv qd. Duration – to decide in hospital.
ALTERNATIVE – Gentamicin 5mg/Kg/day iv followed by therapeutic adjusted to the
susceptibility tests. Duration – to decide in hospital.
Gastrointestinal Extra-biliary complicated intra-abdominal infections152
- Mild-to-moderate severityⱵ 
FIRST LINE – Cefoxitin 2g iv qid, Ertapenem 1g iv qd, Moxifloxacin 400mg iv qd.
ALTERNATIVE – Metronidazole 500mg iv every 8-12 h or 1500mg iv every qd + Cefazolin 
1-2g iv tid, Cefuroxime 1.5g iv tid, Ceftriaxone 1-2g iv every 12-24 h, Cefotaxime 1-2g iv
every 6-8 h, Ciprofloxacin 400mg iv bid or Levofloxacin 750mg iv qd.
High risk or severityϕ 
FIRST LINE – Imipenem-cilastatin 500mg iv qid or 1g tid, Meropenem 1g iv tid or
Piperacillin-tazobactam4.5 g iv qid.
ALTERNATIVE – Metronidazole 500 mg every 8-12h or 1500mg qd + Cefepime 2g every 
8-12h, Ceftazidime 2g tid, Ciprofloxacin 400 mg bid or Levofloxacin 750 mg qd.
Biliary Infections152
Metronidazole 500mg iv qid or 1g iv tid + Meropenem 1g iv tid or Piperacillin-tazobactam 4.5g
iv tid, Cefepime 2g iv every 8-12h, Ciprofloxacin 400mg iv bid or Levofloxacin 750mg iv qd.
Infectious diarrhea169
Campylobacter spp. – Azithromycin 500mg PO daily, 1-3days.
Escherichia coli (enterotoxigenic, enteropathogenic, enteroinvasive) or empiric therapy of
traveler’s diarrhea – Ciprofloxacin 500mg PO bid, 1-3days.
continues on the next page
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Non-typhoid Salmonella spp. – Ciprofloxacin 500mg PO bid, TMP-SMX 160/800 PO bid or
Ceftriaxone 1g iv daily, 14 days.
Shigella spp. – Ciprofloxacin 500mg PO bid or TMP-SMX 160/800 PO bid, 7 days.
Vibrio parahaemolyticus (if severe illness) – Ciprofloxacin 500mg PO bid, 3 days.
Yersinia spp. – Ciprofloxacin 500mg PO bid, TMP-SMX 160/800 PO bid or Doxycycline
100mg bid, 3 days.
Skin and soft tissues Nonpurulentb – Erysipelas/Cellulitis/Necrotizing infection169,170
- Mild
Amoxicillin/Clavulanate 875/125mg PO bid, Cephalosporin (1st or 2nd generation),
Flucloxacillin 500-1000 mg PO tid or Clindamycin 300mg PO qid.
DURATION: 5 days.
- Moderate
Penicillin 2-4 million iv units every 4–6h, Cefazolin 1g iv tid or Clindamycin 600mg iv tid.
DURATION: 5-7 days.
- Severe
Emergency surgical inspection/debridement and Vancomycin 15-20 mg/kg iv every 






Incision and drainage. TMP-SMX 160/800mg PO bid or Doxycycline 100mg PO bid.
DURATION: 5-7 days.
- Severe 
Incision and drainage. Vancomycin 15-20mg/kg iv every 8-12h, Daptomycin, or Linezolid.
DURATION: 5-7 days.
Bone and joints Septic arthritis171,172
- No risk factors for atypical organisms
FIRST LINE – Flucloxacillin 2g iv tid, and/or Gentamicin iv.
ALTERNATIVE – Clindamycin 450-600mg tid iv or Cephalosporin (2nd or 3rd generation) iv.
DURATION: 2-4 weeks.
- High risk of Gram-negative sepsisd
Cefuroxime 1.5g tid iv or ceftriaxone 1-2g bid iv + Flucloxacillin 2g tid iv.
DURATION: 2-4 weeks.
- MRSA riske
Vancomycin 1g bid iv + Cephalosporin (2nd or 3rd generation) iv.
- Suspected gonococcus or meningococcus
Ceftriaxone 1g iv qd (or similar dependent on local policy or resistance).
DURATION: 2-4 weeks.
Infection of articular prosthesis171,173
Orthopedics referral –> decision regarding retention or removal strategy.
Pathogen-specific iv antibiotic therapy (2 to 6 weeks) followed by oral therapy (3-6 months).
Bacterial Osteomyelitis169,174
- Vertebral osteomyelitis
FIRST LINE – Vancomycin (loading dose 20-25mg/Kg, followed by 15-20mg/Kg every 
8h-12h) iv or Cefepime 2g iv tid.
continues on the next page
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ALTERNATIVE – Vancomycin (loading dose 20-25mg/Kg, followed by 15-20mg/Kg every 
8h-12h) iv and/or Ciprofloxacin 400mg iv tid.
DURATION: 4-8 weeks.
- Non vertebral bacterial Osteomyelitis




Sepsis with no clear FIRST LINE – Piperacillin-tazobactam 4.5g iv tid or Cefepime 2g iv tid ± Vancomycin
source169 (loading dose 20-25mg/Kg, followed by 15-20mg/Kg every 8h-12h) iv ± Gentamicin 3mg/kg
iv qd or 1g/Kg iv tid.
ALTERNATIVE – Aztreonam 2g iv tid or Ciprofloxacin 400mg iv tid + Vancomycin (loading
dose 20-25mg/Kg, followed by 15-20mg/Kg every 8h-12h) iv + Gentamicin 3mg/kg iv qd or
1g/Kg iv tid.
Severe infections + respiratory failure54
Extended spectrum beta-lactam + aminoglycoside or a fluoroquinolones.
Suspected intra-abdominal sepsis169
Meropenem 1g iv tid ± Vancomycin (loading dose 20-25mg/Kg, followed by 15-20mg/Kg
every 8h-12h) iv ± Gentamicin 3mg/kg iv id or 1g/Kg tid.
Adapted from161-173
† If intolerance to first line medications. ¤ In patients meeting a CRB-65 of one or more (except age ‡65 as the only criterion met),
hospitalization should be seriously considered. µ Patients without findings reflecting acute respiratory failure, severe sepsis or septic shock and
radiographic extension of infiltrates, as well as severely decompensated comorbidities, should prompt consideration of admission to the ICU or
an intermediate care unit. ○ In men a treatment duration of at least 7 days is recommended, preferably with TMP-SMX or a fluoroquinolone if in
accordance with the susceptibility testing. ◊ If local resistance pattern is known (E. coli resistance < 20%). Ⱶ Perforated or abscessed appendicitis
and other infections of mild-to-moderate severity. ϕSevere physiologic disturbance, advanced age, or immunocompromised state. b Nonpurulent
SSTIs. Mild infection: typical cellulitis/erysipelas with no focus of purulence. Moderate infection: typical cellulitis/erysipelas with systemic signs
of infection. Severe infection: patients who have failed oral antibiotic treatment or those with systemic signs of infection (as defined above under
purulent infection), or those who are immunocompromised, orthoses with clinical signs of deeper infection such as bullae, skins sloughing,
hypotension or evidence of organ dysfunction. c Purulent skin and soft tissue infections (SSTIs). Mild infection: for purulent SSTI, incision and
drainage is indicated. Moderate infection: patients with purulent infection with systemic signs of infection. Severe infection: patients who have
failed incision and drainage plus oral antibiotics; orthoses with systemic signs of infection such as temperature >38°C, tachycardia (heart rate
>90 beats per minute), tachypnea (respiratory rate >24 breaths per minute) or abnormal white blood cell count (<12000 or <400 cells/µL), or
immunocompromised patients. d Elderly, frail, recurrent UTI, and recent abdominal surgery. e Known MRSA, recent inpatient, nursing home
resident, leg ulcers or catheters, or other risk factors determined locally.
ICU – Intensive Care Unit; TMP – trimethoprim; SMX – sulfamethoxazole; qd - once daily; bid – twice a day; tid – three times a day; qid – four
times a day.
OF ELEVATED TRANSAMINASES OF UNKNOWN
AETIOLOGY VIRAL HEPATITIS SCREENING SHOULD
BE REPEATED. IN PRESENCE OF ACTIVE VIRAL
HEPATITIS BIOLOGICAL THERAPY SHOULD BE
DISCONTINUED UNTIL FULL EVALUATION. LEVEL OF
EVIDENCE 5, GRADE OF RECOMMENDATION: D.
Data regarding gastrointestinal infectious complica-
tions are scarce. The SLR retrieve 21 articles, including
27849 patients and a total of 229 (0.82%) cases with
severe gastrointestinal infections events identified, but
none was fatal. Those infections manifested as gas-
troenteritis, colitis, diverticulitis, abdominal abscesses,
appendicitis, and cholangitis. Nevertheless, no evi-
dence is available regarding the best treatment of abdo -
minal infections in patients treated with biolo -
gics3,62,63,81,92,93,102,110,115,119,121,125,126,128,132,136,139,140,146,149.
According to the expert panel, empiric antimicro-
bial therapy should be initiated once the patient re-
ceives a diagnosis of an intra-abdominal infection (ex-
cept non-severe gastroenteritis) (Table IV). Regarding
patients with septic shock, antibiotics should be ad-
ministered as soon as possible, given the poor progno-
sis associated with delayed antimicrobial therapy.152
In the event of a newly diagnosed hepatotropic infec-
tion during biological treatment, viral replication should
be accessed and it is advised to consult a hepatic diseases
specialist. Biologic treatment should be stopped and, if
indicated, antiviral therapy should be started.
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4. SKIN AND SOFT TISSUE INFECTIONS. ORAL OR
INTRAVENOUS EMPIRICAL ANTIBIOTICS SHOULD BE
INITIATED ACCORDING TO THE SEVERITY, WITH
FURTHER ADJUSTMENT GUIDED BY SUSCEPTIBILITY
TESTS. LEVEL OF EVIDENCE: 4, GRADE OF
RECOMMENDATION: C.
From a total of 53799 patients under biologic therapy
reported in 33 studies included in this review, 707
(1.31%) developed skin or soft tissue infections (SSTI)
after a medium exposure of 10.8 months. Only 156
(0.28%) patients had severe complications. Biologics
were stopped in 2 (0.004%) cases. Overall, the use of
TNF-i in RA was not associated with increased risk of
severe SSTI. However, patients with diabetes mellitus
and those with a history of prior skin infection were
significantly more likely to develop severe SSTI (Table
III). There was also a small but significant risk of SSTI
associated with concomitant use of corticosteroids and
advanced age at the start of the TNF-i3,39,62,65,70–73,76,81,83,93,96,
102,104,108,110,112,114,115,119,121,125,127,128,131,132,135,141,143,144,146,149,150,153–157.
The panel suggest that biological therapy should be
initiated with caution, after discussing the relative risks
and benefits, in cases of chronic (example: chronic in-
fected leg ulcers) and recurrent skin and soft tissue in-
fections158.
5. OSTEOARTICULAR INFECTIONS. INTRAVENOUS
BROAD-SPECTRUM EMPIRICAL ANTIBIOTHERAPY
MUST BE PROMPTLY STARTED WITH SUBSEQUENT
ADJUSTMENT ACCORDING TO ANTIBIOTIC
SUSCEPTIBILITY TESTING. OPPORTUNISTIC
INFECTIONS AND ASSOCIATED OSTEOMYELITIS HAVE
TO BE CONSIDERED IN THE EVALUATION OF JOINT
INFECTIONS. ASSESSMENT BY AN ORTHOPAEDIC
SURGEON IS RECOMMENDED, PARTICULARLY IN
PATIENTS WITH OSTEOMYELITIS OR JOINT
PROSTHESIS. LEVEL OF EVIDENCE 2B, GRADE OF
RECOMMENDATION: B.
Osteoarticular infections are always severe and require
prolonged hospitalization. In our SLR, 579 severe os-
teoarticular infections occurred in a total of 11232 pa-
tients under biologics (5.1%), in some cases with iso-
lation of opportunistic agents. The most frequent spe-
cific risk factors were joint prosthesis, therapy with GCs
(prednisolone more than 10 mg), opportunistic infec-
tions, advanced age, existence of extra-articular mani-
festations (in RA), depletion of B cells, so in the evalua -
tion of joint infections, these specific risks (Table
III)3,68,76,81,87,93,106,115,119,125,141,145,149,159–162. Assessment by an
orthopaedic surgeon should be requested, namely
when concomitant osteomyelitis is suspected or infec-
tion of a prosthetic joint is involved. Intravenous broad-
-spectrum empirical antibiotherapy should be prom -
ptly started and subsequently adjusted according to the
antimicrobial susceptibility testing (Table IV). After
complete resolution of infection, the reintroduction of
the biological must be weighted based on the activity
of rheumatic disease and the risk of reinfection. 
6. DISSEMINATED INFECTION. EPIDEMIOLOGICAL
CONTEXT SHOULD GUIDE DIAGNOSTIC STUDIES.
IMMUNOSUPPRESSIVE TREATMENT MUST BE STOPPED
AND BROAD-SPECTRUM EMPIRICAL ANTIBIOTHERAPY
INTRODUCED IMMEDIATELY. IN THE ABSENCE OF
CLINICAL RESPONSE AFTER 48-72 HOURS,
CONSIDER LESS COMMON AGENTS SUCH AS FUNGI,
VIRUSES, PARASITES AND MYCOBACTERIA. LEVEL
OF EVIDENCE: 4, GRADE OF RECOMMENDATION: C.
Disseminated infection means the involvement of mul-
tiple organs by the same pathogen. In patients under
bio logical therapy, disseminated infections are severe
and often caused by opportunistic agents68,73,108,124,154,159.
In our SLR, 23 out of 3668 patients under biologics
(0.6%), developed a disseminated infection, with the
highest risk between 8- 36 months after initiating bio-
logics and in patients with advance age, long-standing
rheumatic disease, history of recurrent infections, co-
morbidities, treated with concomitant csDMARDs and
GCs (Table III)68,73,108,154,159,160. The epidemiological con-
text should guide the diagnostic tests. These studies
should include the collection of biological products for
cultural examination, histology and serology73,159,160.
Immunosuppressive treatment must be stopped and
broad-spectrum empirical antibiotherapy introduced
immediately (Table IV). In the absence of clinical res -
ponse after 48-72 hours, consider less common agents
such as fungi, viruses, parasites and mycobacte-
ria68,73,108,124,154,159. After complete resolution of infection,
reintroduction of biologic must be weighted based on
the activity of rheumatic disease and risk of reinfec-
tion108,160.
dIscussIon
Although infections occur frequently and may be severe
in patients under biological therapies, the best mana -
gement remains mostly empirical. After an extensive
literature review, we did not retrieve necessary infor-
mation about the best management of infections in pa-
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tients under biologics. There is no sufficient data on
the clinical presentation or the laboratorial features of
the infectious disease, the treatment, discontinuation of
the biologic and other anti-rheumatic medications and
their reintroduction. Given the scarcity of data from
the literature, most of the recommendations are pri-
marily based on expert opinion.
conclusIons
These fifteen recommendations, integrating an exten-
sive literature review and the opinion of clinical ex-
perts, were issued to help the clinical decision.
There is a scarcity of evidence concerning the best
management of infections in patients treated with bio-
logics. Most RCTs lack information on the management
of infectious complications arising during treatment
with biologics. Registries can provide useful informa-
tion to fill this gap. As more information becomes avai -
lable, these recommendations will be updated.
For divulgation purposes, the current paper will be
published in a MEDLINE-indexed journal and freely
available online at the website of the Portuguese Socie -
ty of Rheumatology. All members of the Society will be
notified by email and/or newsletter after publication.
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